January 2024
Molecular Profiling of Circulating Tumour Cells and Circulating Tumour DNA: Complementary Insights from a Single Blood Sample Utilising the Parsortix SystemANGLE Europe Limited, Guildford, UK published by journal of Current Issues in Molecular Biology
December 2023
Plasminogen activator inhibitor 1 is associated with high-grade serous ovarian cancer metastasis and is reduced in patients who have received neoadjuvant chemotherapyTrinity College Dublin, Ireland published by the journal Frontiers in Cell and Developmental Biology
November, 2023
Targeting Translation and the Cell Cycle Inversely Affects CTC Metabolism but Not MetastasisDepartment of Internal Medicine, University of New Mexico Health Sciences Center, United States
November, 2023
DanioCTC: Analysis of Circulating Tumor Cells from Metastatic Breast Cancer Patients in Zebrafish XenograftsDepartment of Obstetrics and Gynaecology, Heinrich Heine University of Duesseldorf, Germany
October, 2023
Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotypingInstitute of Cancer and Genomic Sciences, University of Birmingham, UK, published by the British Journal of Cancer
September, 2023
Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer PatientsResearch Institute for Women’s Health, University of Tubingen, Tubingen, Germany published by International Journal of Molecular Sciences
August, 2023
Analytical performance of the FDA-cleared Parsortix®PC1 systemANGLE Europe Limited, Guildford, UK published by Journal of Circulating Biomarkers
August, 2023
Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck CancerNational and Kapodistrian University of Athens, Athens, Greece published by Cancer Research Communications
June, 2023
Innovative Approach to Isolate and Characterize Glioblastoma Circulating Tumor Cells and Correlation with Tumor Mutational StatusFondazione Pisana per la Scienza, San Giuliano Terme, Pisa, Italy, published by International Journal of Molecular Sciences
June, 2023
Protocol for a prospective study evaluating circulating tumour cells status to predict radical prostatectomy treatment failure in localised prostate cancer patients (C‑ProMeta‑1)Dept. of Urology, University College London Hospitals, London, UK, published by BMC Cancer
June, 2023
Association of Circulating Tumor Cells, Megakaryocytes and a High Immune-Inflammatory Environment in Metastatic Breast CancerDepartment Medical Oncology, Institute of Oncology, Ljubljana, Slovenia, published by Cancers
May, 2023
Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate CancerDepartment of Urology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands, published by International Journal of Molecular Sciences
March, 2023
Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patientsGerman Center for Lung Research, Grosshansdorf, Germany, published by Molecular Oncology, March 2023
March, 2023
Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung CancerNational and Kapodistrian University of Athens, Athens, Greece published by Cancers
March, 2023
The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patientsUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany, published by Cancer Cell International
January, 2023
The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancerBarts Cancer Institute, Queen Mary University of London, London, United Kingdom, published by Frontiers in Oncology
November, 2022
Circulating Cancer Associated Macrophage-like Cells as a Potential New Prognostic Marker in Pancreatic Ductal AdenocarcinomaUniversity Hospital Hamburg-Eppendorf, Hamburg, Germany, published by Biomedicines
November, 2022
Effect of short-term storage of blood samples on gene expression in lung cancer patientsMedical University of Vienna, Vienna, Austria, published by Clinical Chemistry and Laboratory Medicine
November, 2022
The RPL/RPS Gene Signature of Melanoma updates CTCs Associates with Brain MetastasisUniversity of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA, published by Cancer Research Communications
October, 2022
A Multi-Center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix®PC1 SystemUniversity of Texas MD Anderson Cancer Center, Houston, Texas, USA; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York, USA; Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA; Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA , published by Cancers
October, 2022
Comparative analysis of capture methods for genomic profiling of circulating tumor cells in colorectal cancerUniversidade de Vigo, Vigo, Spain and the Galicia Sur Health Research Institute , Spain, published by Genomics,
September, 2022
Characterization of RARRES1 Expression on Circulating Tumor Cells as Unfavorable Prognostic Marker in Resected Pancreatic Ductal Adenocarcinoma PatientsUniversity Hospital Hamburg-Eppendorf, Hamburg, Germany, published by Cancers
September, 2022
Comparison of microfuidic platforms for the enrichment of circulating tumor cells in breast cancer patientsDepartment of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, published by Breast Cancer Research and Treatment
September, 2022
Malignancy Assessment Using Gene Identification in Captured Cells Algorithm for the Prediction of Malignancy in Women With a Pelvic MassDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Wilmot Cancer Institute, University of Rochester, Rochester, New York and ANGLE Europe Limited, Surrey Research Park, Guildford, Surrey, United Kingdom, published by Obstetrics & Gynecology
July, 2022
Characterizing the epithelial–mesenchymal transition status of circulating tumor cells in head and neck squamous cell carcinomaInstitute of Head and Neck Studies and Education, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom, published by Head and Neck
July, 2022
Powering single‑cell genomics to unravel circulating tumour cell subpopulations in non‑small cell lung cancer patientsEdith Cowan University, Perth, Australia, published by Journal of Cancer Research and Clinical Oncology
June, 2022
Implementing microwell slides for detection and isolation of single circulating tumor cells from complex cell suspensionsUniversity Hospital and Medical Faculty, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, published by Cytometry
June, 2022
Metabolism-Related Gene Expression in Circulating Tumor Cells from Patients with Early Stage Non-Small Cell Lung CancerNational and Kapodistrian University of Athens, Greece, published by Cancers
June, 2022
The metastatic spread of breast cancer accelerates during sleepMolecular Oncology Laboratory at the Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, published by Nature
May, 2022
DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detectionNational and Kapodistrian University of Athens, Greece, published by Clinical Epigenetics
May, 2022
Evaluation of PD-L1 expression on circulating tumour cells in small-cell lung cancerSchool of Medical and Health Sciences, Edith Cowan University, Perth, Australia, published by Translational Lung Cancer Research
April, 2022
Invadopodia play a role in prostate cancer progressionSchool of Cancer and Pharmaceutical Sciences, King’s College London, London, UK, published by BMC Cancer
March, 2022
Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and SarcomaFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, published by Clinical Chemistry
February, 2022
An in vivo CRISPR screen identifies stepwise genetic dependencies of metastatic progressionMolecular Oncology Laboratory, Swiss Federal Institute of Technology (ETH) Zurich, Switzerland, published by Cancer Research
February, 2022
Microtubule disruption reduces metastasis more effectively than primary tumor growthUniversity of Maryland Marlene and Stewart Greenebaum NCI Comprehensive Cancer Institute, Baltimore, Maryland, USA, published by Breast Cancer Research
January, 2022
Cyclooxygenase 2 Effector Genes as Potential Inflammation-Related Biomarkers for Colorectal Cancer Circulating Tumor Cells Detection by Liquid BiopsyUniversidad Autonoma de Madrid, Madrid, Spain, published by Frontiers in Pharmacology
January, 2022
Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early‑stage triple negative breast cancerFondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, published by Scientific Reports
January, 2022
Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast CancerUniversity of Southern California Norris Cancer Center, Los Angeles, United States, published by Annals of Surgical Oncology
December, 2021
Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer PatientsEdith Cowan University, Perth, Australia, published by Cancers
November, 2021
DNA Methylation Analysis in Plasma Cell-Free DNA and Paired CTCs of NSCLC Patients before and after Osimertinib TreatmentNational and Kapodistrian University of Athens, Greece, published by Cancers
November, 2021
Cancer Stem Cell-like Circulating Tumor Cells Are Prognostic in Non-Small Cell Lung CancerMolecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Austria, published by Journal of Personalized Medicine
November, 2021
Immediate Sample Fixation Increases Circulating Tumour Cell (CTC) Capture and Preserves Phenotype in Head and Neck Squamous Cell Carcinoma: Towards a Standardised Approach to Microfluidic CTC Biomarker DiscoveryInstitute of Head and Neck Studies and Education, Institute of Cancer and Genomic Sciences, University of Birmingham, UK, published by Cancers
August, 2021
Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small cell lung cancer treated with pembrolizumabLiquid Biopsy Analysis Unit, Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), Santiago de Compostela, Spain published by Molecular Oncology
August, 2021
Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate CancerDepartment of Urology, Medical University Innsbruck, Innsbruck, Austria published by Biomedicines
July, 2021
Whole-genome sequencing of single circulating tumor cells from neuroendocrine neoplasmsUCL Cancer Institute, University College London, London, UK, published by Endocrine-Related Cancer
July, 2021
Morphological features of breast cancer circulating tumor cells in blood after physical and biological type of isolationDepartment of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia published by Radiology and Oncology
June, 2021
CD74 and CD44 Expression on CTCs in Cancer Patients with Brain MetastasisUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany published by International Journal of Molecular Sciences
May, 2021
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCRNational and Kapodistrian University of Athens, Greece published by Cancers
May, 2021
A microfluidic-based filtration system to enrich for bone marrow disseminated tumor cells from breast cancer patientsWashington University School of Medicine, St. Louis, Missouri, United States published by PLoS ONE
May, 2021
Evaluation of a marker independent isolation method for circulating tumor cells in esophageal adenocarcinomaDepartment of Gastro-Intestinal Surgery, University Hospital Ghent, Belgium published by PLoS ONE
April, 2021
Evaluation of Monocarboxylate Transporter 4 (MCT4) Expression and Its Prognostic Significance in Circulating Tumor Cells From Patients With Early Stage Non-Small-Cell Lung CancerNational and Kapodistrian University of Athens, Athens, Greece published by Frontiers in Cell and Developmental Biology
March, 2021
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapyFondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy published by ESMO Open / Cancer Horizons
February, 2021
Cysteine-Rich Angiogenic Inducer 61: Pro-Survival Function and Role as a Biomarker for Disseminating Breast Cancer CellsUniversity Medical Centre Hamburg-Eppendorf, Hamburg, Germany published by Cancers
January, 2021
Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD‑L1during osimertinib treatment in NSCLC patientsNational and Kapodistrian University of Athens, Greece published by Nature Scientific Reports
January, 2021
Proficiency testing to assess technical performance for CTC-processing and detection methods in CANCER-IDThe CANCER-ID Consortium published by Clinical Chemistry
January, 2021
EMT‑independent detection of circulating tumor cells in human blood samples and pre‑clinical mouse models of metastasisLondon Regional Cancer Program and Flow Cytometry, London Health Sciences Centre; Departments of Anatomy & Cell Biology and Oncology, Western University; and Lawson Health Research Institute, London, Ontario, Canada published by Clinical & Experimental Metastasis,
October, 2020
Antigen-agnostic microfluidics based circulating tumor cell enrichment and downstream molecular characterizationDivision of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, United States published by PLOS ONE
September, 2020
Hypoxia Triggers the Intravasation of Clustered Circulating Tumor CellsDepartment of Bioscience, Cancer Metastasis Laboratory, University of Basel and University Hospital Basel, Switzerland published by Cell Reports
July, 2020
A Pilot Study for the Feasibility of Exome-Sequencing in Circulating Tumor Cells Versus Single Metastatic Biopsies in Breast CancerUniversity of Southern California Norris Comprehensive Cancer Center, Los Angeles, United States published by International Journal of Molecular Sciences
June, 2020
Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 ImmunotherapyLaboratory of Translational Oncology, School of Medicine, University of Crete, Greece published by Cancers
April, 2020
Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinomaUniversity of Athens, Greece published by Nature Scientific Reports
February, 2020
Detection of MET Alterations Using Cell Free DNA and Circulating Tumor Cells from Cancer PatientsLiquid Biopsy Analysis Unit, Health Research Institute of Santiago, Spain published by Cells
February, 2020
Cancer transcriptomic profiling from rapidly enriched circulating tumor cellsKeck School of Medicine, University of Southern California, United States published by International Journal of Cancer
February, 2020
ALCAM contributes to brain metastasis formation in non-small-cell lung cancer through interaction with the vascular endotheliumUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Journal of Neuro-Oncology
February, 2020
Analysis of Single Circulating Tumor Cells in Renal Cell Carcinoma Reveals Phenotypic Heterogeneity and Genomic Alterations Related to ProgressionFondazione IRCCS Istituto Nazionale Tumori, Milano, Italy published by International Journal of Molecular Sciences
February, 2020
Pre-Analytical and Analytical Variables of Label-Independent Enrichment and Automated Detection of Circulating Tumor Cells in Cancer PatientsUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Cancers
February, 2020
Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cellsEdith Cowan University, Perth, Australia published by British Journal of Cancer
October, 2019
Intra-Patient Heterogeneity of Circulating Tumor Cells and Circulating Tumor DNA in Blood of Melanoma PatientsUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Cancers
September, 2019
Non-invasive detection of clinically significant prostate cancer using circulating tumor cellsBarts Cancer Institute, Queen Mary University of London, UK published by Journal of Urology
August, 2019
Circulating Tumour Cell Biomarkers in Head and Neck Cancer: Current Progress and Future ProspectsInstitute of Head and Neck Studies and Institute of Immunology and Immunotherapy, University of Birmingham, UK published by Cancers
August, 2019
Molecular Characterization of Circulating Tumor Cells Enriched by A Microfluidic Platform in Patients with Small-Cell Lung CancerMedical University of Vienna, Austria published by Cells
June, 2019
Diagnostic Leukapheresis Enables Reliable Transcriptomic Profiling of Single Circulating Tumor Cells to Characterize Inter-Cellular Heterogeneity in Terms of Endocrine ResistanceUniversity Hospital and Medical Faculty of the Heinrich-Heine University Duesseldorf, Germany published by Cancers
June, 2019
Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 InhibitorsDepartment of Oncology, Hematology and Bone Marrow Transplantation with section Pneumology, Hubertus Wald University Comprehensive Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany published by Cancers
April, 2019
PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal SignalingBiomarker Research Program, Houston Methodist Research Institute in conjunction with the Center for Precision Health, University of Texas and MD Anderson Cancer Center, Houston, United States published by International Journal of Molecular Sciences
March, 2019
Assessing metastatic potential of breast cancer cells based on EGFR dynamicsThe University of Texas MD Anderson Cancer Center, Houston, United States published by Nature
February, 2019
Label-Free Enrichment and Molecular Characterization of Viable Circulating Tumor Cells from Diagnostic Leukapheresis ProductsDisseminated Cancer Cell Network (DCCNet) at the University Hospital and Medical Faculty of the Heinrich-Heine University of Duesseldorf, Duesseldorf, Germany published by Clinical Chemistry
February, 2019
Neutrophils escort circulating tumour cells to enable cell cycle progressionCancer Metastasis Laboratory, University of Basel and collaborators published by Nature
January, 2019
Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samplesFraunhofer Institute for Toxicology and Experimental Medicine, Regensburg, Germany published by International Journal of Cancer
January, 2019
Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis SeedingCancer Metastasis Laboratory, University of Basel and collaborators published by Cell
November, 2018
Denosumab treatment is associated with the absence of circulating tumor cells in patients with breast cancerCancer Metastasis Laboratory, University of Basel, Switzerland published by Breast Cancer Research
August, 2018
Detection of circulating tumour cell clusters in human glioblastomaCancer Metastasis Laboratory, University of Basel and collaborators published by British Journal of Cancer
July, 2018
The Parsortix®Cell Separation System – A Versatile Liquid Biopsy PlatformANGLE plc published by Cytometry Part A, Journal of Quantitative Cell Science
March, 2018
The precious cell blockDepartment of Cellular Pathology, Musgrove Park Hospital, Taunton UK published by the Journal of Clinical Pathology
January, 2018
Challenges in using liquid biopsies for gene expression profilingUniversity of Southern California Norris Comprehensive Cancer Center published by Oncotarget
January, 2018
In Situ Detection and Quantification of AR-V7, AR-FL, PSA, and KRAS Point Mutations in Circulating Tumor CellsUniversity Medical Centre Hamburg-Eppendorf, Medical University of Graz and Stockholm University published by Clinical Chemistry
November, 2017
Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cellsMedical University of Vienna published by Oncotarget
September, 2017
Comparison of isolation platforms for detection of circulating renal cell carcinoma cellsClinic for Urology, University Hospital Muenster, Muenster, Germany published by Oncotarget
August, 2017
A novel workflow to enrich and isolate patient-matched EpCAM high and EpCAM low/negative CTCs enables the comparative characterization of the PIK3CA status in metastatic breast cancerHeinrich Heine University of Dusseldorf published by International Journal of Molecular Sciences
June, 2017
The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosisBarts Cancer Institute published by Clinical Cancer Research
September, 2016
Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor CellsUniversity Medical Centre Hamburg-Eppendorf (UKE) published by Clinical Chemistry
January, 2016
A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cellsUniversity Medical Centre Hamburg-Eppendorf (UKE) published by International Journal of Cancer
November, 2015
Clinical evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumor cells in patients with small cell lung cancerCancer Research UK Manchester Institute and Christie NHS Foundation Trust, Manchester UK published by Royal Society of Chemistry Analyst publication
September, 2015
Optimization and Evaluation of a Novel Size Based Circulating Tumor Cell Isolation SystemBarts Cancer Institute, published by PLOS ONE
March 2024
Integrating isolation using label-independent microfluidics and advanced staining for comprehensive Circulating Tumour Cell AnalysisANGLE Europe Limited, Guildford, UK, published at the 14th European Breast Cancer Conference March 22 2024
March 2024
Interrogating HER2 status in Circulating Tumor Cells isolated using the Parsortix® System from Metastatic Breast Cancer patientsANGLE Europe Limited, Guildford, UK, published at the 14th European Breast Cancer Conference March 22 2024
May, 2023
Detection and molecular characterization of EpCAM positive and EpCAM negative circulating tumor cells isolated from SCLC (small cell lung cancer) patients using an epitope independent platformCancer Research UK Manchester Institute, as presented at the 10th ISMRC International Symposium on Minimal Residual
May, 2023
Integration of RNA and DNA blood-borne cancer biomarkersCancer Research UK Manchester Institute, as presented at the 10th ISMRC International Symposium on Minimal Residual
April, 2023
Evaluation of HER2 status in circulating tumour cells isolated using ANGLE’s Parsortix®SystemANGLE Europe Limited as presented at the American Association for Cancer Research, Florida, USA
March, 2023
Detection of DNA Damage in Circulating Tumor Cells Isolated using the Parsortix®SystemANGLE plc as presented at the European Association for Cancer Research, Florence, Italy
December, 2022
Identification of circulating tumor cells captured by the FDA cleared Parsortix®PC1 System from the peripheral blood of metastatic breast cancer patients using immunofluorescence and cytopathological evaluationsANGLE Europe Limited as presented at the San Antonio Breast Cancer Symposium, Texas, USA
December, 2022
A Multi-center Clinical Study to Harvest and Characterize Circulating Tumor Cells from Patients with Metastatic Breast Cancer Using the Parsortix®PC1 System in support of FDA clearanceMD Anderson Cancer Center as presented at the San Antonio Breast Cancer Symposium, Texas, USA
October, 2022
Maximizing clinical utility of liquid biopsy utilizing a single blood sample for ctDNA and CTC analysis using the Parsortix®SystemANGLE Europe Limited as presented at the 4th Annual International Society of Liquid Biopsy Congress in Miami, Florida, USA
September, 2022
Morphological Characteristics of Malignancy in Circulating Tumor CellsANGLE Onc-ADaPT Labs as presented at the 100th American Society of Clinical Pathology (ASCP) Meeting in Chicago, Illinois, USA
May, 2022
Antigen-independent enrichment of circulating tumour cells in metastatic breast and ovarian cancerTrinity College Dublin as presented at EACR Liquid Biopsies Conference
April, 2022
Epithelial and Mesenchymal CTC Detection in Triple Negative Breast Cancer Patients using ANGLE’s Parsortix®SystemANGLE plc, as presented at AACR
8-12 November, 2021
Circulating Tumour Cell Analysis to Evaluate Docetaxel Treatment Response and Resistance Markers in Prostate CancerBarts Cancer Institute, Queen Mary University of London, UK as presented at NCRI Festival
September, 2021
Detection of circulating tumor cells in platinum-resistant ovarian cancer patients enrolled in the GANNET53 studyMedical University of Vienna, Austria as presented at the Fifth Advances in Circulating Tumour Cells (ACTC) Meeting in Kalamata, Greece
September, 2021
Molecular characterization of circulating tumor cells enriched by a microfluidic platform in patients with non-small cell lung cancerMedical University of Vienna, Austria as presented at the Fifth Advances in Circulating Tumour Cells (ACTC) Meeting in Kalamata, Greece
September, 2021
Detection of p53 aggregates in circulating tumour cells of patients with small cell lung cancerMedical University of Vienna, Austria as presented at the Fifth Advances in Circulating Tumour Cells (ACTC) Meeting in Kalamata, Greece
April - May, 2021
Mesenchymal markers: the new avenue for circulating tumor cells detectionANGLE plc as presented at AACR 2021 Virtual Meeting
April - May, 2021
Investigation of PD-L1 expression in circulating tumor cells isolated using the Parsortix®system in metastatic lung and breast cancer patientsANGLE plc as presented at AACR 2021 Virtual Meeting
March, 2020
Isolation of ovarian cancer circulating tumor cells using an epitope independent microfluidic cell capture device and their interrogation using a multiplex gene expression assay or immunofluorescenceANGLE plc and University of Rochester Medical Center, Wilmot Cancer Institute as presented at SGO
March - April, 2019
Molecular characterisation of circulating tumor cells in head and neck squamous cell carcinoma: Direct comparison of a label-independent size-based microfluidic device with EpCAM-based CTC enrichmentUniversity of Athens, Greece as presented at AACR 2019 in Atlanta, United States
March - April, 2019
Molecular characterization of circulating tumor cells in cholangiocarcinoma patients: A new tool for treatment management?Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy as presented at AACR 2019 in Atlanta, United States
March - April, 2019
Increased chromatin heterogeneity in circulating tumor cells (CTCs) is associated with high levels of HER2 expression in metastatic breast cancer (MBC)Northwestern University, Chicago, United States as presented at AACR 2019 in Atlanta, United States,
March - April, 2019
Detection of CK-19 mRNA positive CTCs, isolated with a size-based microfluidics platform, in NSCLC patients under osimertinib therapyUniversity of Athens, Greece as presented at AACR 2019 in Atlanta, United States
March - April, 2019
Parsortix®system: Analytic performance evaluation using ovarian cancer cell linesANGLE plc as presented at AACR 2019 in Atlanta, United States
March - April, 2019
Multiplex gene expression using the HyCEAD assay in CTCs isolated with the Parsortix®systemANGLE plc as presented at AACR 2019 in Atlanta, United States,
October, 2018
A novel method to enrich and characterize circulating fetal cells using the Parsortix®cell separation systemANGLE plc as presented at the 6th Annual Advances in Prenatal Molecular Diagnostics conference in Cambridge
May, 2018 (ISMRC 2018)
CTCs in Prostate Cancer: Molecular Characterization, Immunostaining and Enumeration by Combination of Label-free Parsortix®CTC Enrichment and AdnaTest Prostate Cancer Panel Expression Profiling for PSMA, AR and AR-V7ANGLE plc and QIAGEN GmbH as presented at the 11th International Symposium on Minimal Residual Cancer in Montpellier, France,
April, 2018
A novel ex vivo culture workflow to enrich and expand circulating tumor cells (CTCs) from patients with Stage III/IV Breast CancerRobert H Lurie Comprehensive Cancer Center and the Feinberg School of Medicine, Northwestern University, Chicago as presented at AACR 2018 in Chicago
April, 2018
A fast and sensitive workflow to screen therapy-relevant mutations in circulating tumor cells and quantification of cancer-associated exosomal mRNA in plasma of cancer patientsBayer AG, Pharmaceutical Division as presented at AACR 2018 in Chicago
March, 2018
Ember Trial: Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting with a Pelvic MassANGLE plc and University of Rochester Medical Center, Wilmot Cancer Institute as presented at SGO
December, 2017
The whole transcriptional landscape of circulating tumor cells compared to metastases in stage IV breast cancerUniversity of Southern California Norris Comprehensive Cancer Center as presented at the San Antonio Breast Cancer Symposium in Texas
November, 2017
Highly Multiplexed Molecular Analysis of Circulating Tumor Cells Enriched Using the Epitope Independent Parsortix®SystemANGLE plc as presented at the AACC Emerging Clinical & Laboratory Diagnostics in the Healthcare Ecosystem (ECLD) conference in San Diego
October, 2017
Establishment and evaluation of a novel method for the size separation of disseminated tumor cells from cancer patient bone marrow by a microfluidic platformUniversityclinic Tuebingen, Germany as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes
October, 2017
Parsortix®system enables isolation of viable CTCs from leukapheresis product with subsequent cultureHeinrich-Heine University Duesseldorf, Germany as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes
October, 2017
The novel association of circulating tumour cells and circulating megakaryocytes with prostate cancer prognosisBarts Cancer Institute, Queen Mary University of London as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes
October, 2017
Single CTC isolation for genetic analysis using Parsortix®and VyCAPVyCAP B.V. as presented at the Third International Advances in Circulating Tumour Cells (ACTC) Symposium in Rhodes
August, 2016 (AACC 2016)
Antibody-free microfluidics-based circulating tumor cell enrichment by Parsortix®and downstream molecular characterization by Quantigene branched DNA technologyMD Anderson as presented at the 68th AACC Annual Scientific Meeting & Clinical Lab Expo in Philadelphia
July, 2016 (EACR 2016)
Surface marker independent enrichment of circulating or disseminated cancer cells from blood or lymph nodes using a micro-fluidic deviceFraunhofer ITEM as presented at the 24th Biennial Congress of the European Association for Cancer Research
July, 2016 (EACR 2016)
A highly sensitive method for circulating tumor cell antigen quantification in liquid biopsyANGLE Research & Development Laboratory as presented at the 24th Biennial Congress of the European Association for Cancer Research
April, 2016
Combined circulating tumor cell (CTC) and circulating tumor DNA (ctDNA) analysis of blood from patients with pancreatic cancerCancer Research UK Manchester Institute as presented at the American Association for Cancer Research Annual Meeting
March, 2016
The combination of Parsortix®system and CellCelector™ micromanipulator enables the characterization of EpCAM negative circulating tumor cells in breast cancerHeinrich-Heine University, Düsseldorf, Germany as presented at the 10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment
September, 2015
Circulating rare cells enable highly efficient cancer detectionMedical University of Vienna, as presented at 18th ECCO – 40th ESMO European Cancer Congress
11 June, 2015
Intra-tumor heterogeneity in prostate cancer and the implication in CTC analysisBarts Cancer Institute, as presented at a symposium hosted by the British Association for Cancer Research and Cancer Research UK on
April, 2015
Circulating rare cells enable highly efficient cancer detectionMedical University of Vienna, as presented at the AACR conference
April, 2015
Enrichment and isolation of uncontaminated breast cancer cells from human blood samplesSidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, as presented at the AACR conference
November, 2014
Evaluation of a novel microfluidic device for epitope-independent enrichment of circulating tumor cellsCRUK – Manchester, as presented at NCRI conference
October, 2014
Technical validation of a novel label-independent device to capture CTCsThe University Medical Center Hamburg-Eppendorf (UKE), as presented at ACTC Conference
May, 2023
Liquid Biopsy in Cancer Care – Improving Patient Outcomes and Reducing Healthcare CostsPublished by International Clinical Trials, © Samedan Ltd.
August, 2022
ANGLE achieves world first with FDA clearance for its Parsortix PC1 clinical systemPublished by SHARES spotlight
May, 2021
ANGLE plc -Transforming cancer care with a liquid biopsy from a simple blood testPublished by SHARES spotlight
January, 2021
The impact of COVID-19 on cancer diagnosis and careAndrew Newland, CEO ANGLE plc, published by European Biopharmaceutical Review
May, 2023
Parsortix®Small Volume CapabilitiesParsortix® Cell Separation System Small Volume Capabilities
September 7 – 21 October, 2021
Development of standardized epithelial and mesenchymal CTC + PD-L1 assay for Parsortix®systemPresentation to the American Association for Cancer Research conference
24 May, 2018
The epitope-independent Parsortix®system enables isolation, identification and analysis of epithelial and mesenchymal CTCsPresentation to the Sixth International Molecular Diagnostics Europe conference
More resources
Webinars
Watch the latest developments related to liquid biopsy and circulating tumor cells
Watch webinarsProduct information
Download brochures, application notes and Instrument User Guides
View product information